LTA and myeloid sarcoma: The reduced memory B cell profile seen after rituximab treatment in MS may also apply to NMO, with reconstituting B cells secreting reduced IL-6 as well as other inflammatory cytokines, including TNF-α and LTa (Bar-Or et al., 2010; Barr et al., 2012).